FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia.

Blood
T LinJohn C Byrd

Abstract

The in vivo mechanism of action of alemtuzumab (anti-CD52; Campath-1H) remains unclear. With rituximab, FCGR3A and FCGR2A high-affinity polymorphisms have been associated with clinical response in lymphoma but not in CLL, suggesting potential divergent mechanisms of action between these 2 diseases. Herein, we examined FCGR3A (V/V, n = 4; V/F, n = 10; F/F, n = 19) and FCGR2A (A/A, n = 5; H/A, n = 22; H/H, n = 6) polymorphisms in 36 patients with relapsed CLL who were treated with thrice-weekly alemtuzumab for 12 weeks to assess the potential influence these high-affinity FcgammaR receptor polymorphisms had on response to alemtuzumab. Response to alemtuzumab was similar regardless of FCGR3A polymorphism (V/V, 25%; V/F, 40%; F/F, 32%) or FCGR2A polymorphism (A/A, 40%; H/A, 32%; H/H, 33%). These findings indicate that FCGR3A and FCGR2A polymorphisms may not predict response to alemtuzumab in CLL. Future studies examining larger cohorts of alemtuzumab-treated patients with CLL will be required to definitively determine the predictive value of specific FCGR polymorphisms to treatment response.

References

Jul 17, 1995·Journal of Immunological Methods·A K Patel, P N Boyd
Mar 17, 1995·The Journal of Biological Chemistry·A TreumannM A Ferguson
Apr 1, 1994·Journal of Clinical Pathology·J R SalisburyA B Nethersell
Dec 1, 1996·Clinical and Experimental Immunology·J D IsaacsH Waldmann
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A OsterborgH Mellstedt
Mar 31, 2000·Nature Medicine·R A ClynesJ V Ravetch
Nov 21, 2000·Current Opinion in Oncology·J M Flynn, J C Byrd
Aug 9, 2002·The New England Journal of Medicine·Stephan Stilgenbauer, Hartmut Döhner
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K R RaiL Brettman
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rajat BannerjiJohn C Byrd
Apr 22, 2003·The Journal of Allergy and Clinical Immunology·Bryce A BinstadtFrancisco A Bonilla
Sep 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wen-Kai Weng, Ronald Levy

❮ Previous
Next ❯

Citations

Sep 28, 2005·Cancer Immunology, Immunotherapy : CII·Bruce D Cheson
Nov 4, 2008·Cancer Immunology, Immunotherapy : CII·Rodney J TaylorScott E Strome
Jun 10, 2006·Nature Reviews. Drug Discovery·Cecile KrejsaWolfgang Sadee
Mar 31, 2012·Nature Reviews. Drug Discovery·P Mark Hogarth, Geoffrey A Pietersz
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
Jan 1, 2010·Biotechnology & Genetic Engineering Reviews·Roy Jefferis
Oct 24, 2006·Pharmacogenomics·Li Yan, Hugh M Davis
Feb 28, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Raghvendra M SrivastavaRobert L Ferris
May 15, 2008·Expert Opinion on Biological Therapy·Siao-Yi Wang, George Weiner
Jun 28, 2011·Expert Opinion on Biological Therapy·Xavier Poiré, Koen van Besien
Aug 31, 2007·Expert Opinion on Biological Therapy·Roy Jefferis
Sep 29, 2005·Expert Opinion on Biological Therapy·David Ternant, Gilles Paintaud
Nov 23, 2006·Cancer Investigation·Farhad Ravandi, Susan O'brien
Jan 24, 2007·Critical Reviews in Oncology/hematology·Sophie SibérilJean-Luc Teillaud
Jun 10, 2006·Hematology/oncology Clinics of North America·Raphael Clynes
Aug 15, 2006·Advanced Drug Delivery Reviews·Leonard G Presta
Apr 3, 2016·Current Opinion in Immunology·Peter Sondermann, David E Szymkowski
May 25, 2006·Seminars in Oncology·Bruce D Cheson
Aug 20, 2005·Journal of Immunological Methods·Julie A Bowles, George J Weiner
Jun 6, 2015·Cancer Treatment Reviews·D Pérez-CallejoM Sánchez-Beato
Feb 9, 2010·Journal of Immunological Methods·Kathryn L ArmourMichael R Clark
Oct 27, 2015·Immunological Reviews·Lekh N DahalMark S Cragg
Jan 24, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frédéric BibeauFlorence Boissière-Michot
Mar 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonino MusolinoAndrea Ardizzoni
Aug 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wu ZhangHeinz-Josef Lenz
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William G WierdaMichael J Keating
Dec 17, 2017·Immunology·Nicolas DubuissonKlaus Schmierer
Jan 1, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yvonne GuettingerBernhard Stockmeyer
May 7, 2020·Journal of Hematology & Oncology·Jifeng YuWenzhi Tian
Jan 7, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Guillaume CartronMichael Hallek

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.